Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corpor...(share data) ...),Health

Date:5/5/2009

share data) (Unaudited) Three Months Ended March 31, ------------- 2009 2008 ---- ---- Revenues $- $- -- -- Operating expenses: Research and development 8,104 6,336 General and administrative 3,084 4,183 Restructuring & asset impairment 1,056 - ----- - Total operating expenses 12,244 10,519 ------ ------ Loss from operations (12,244) (10,519) ------- ------- Other income (expense), net (706) 664 ---- --- Net loss (12,950) (9,855) Preferred stock dividends (125) (125) ---- ---- Loss applicable to common shares $(13,075) $(9,980) ======== ======= Loss per share: Basic and diluted $(0.38) $(0.29) ====== ====== Shares used in calculation of loss per share: Basic and diluted 34,688 34,681 ====== ====== Condensed Consolidated Balance Sheets (In thousands) (Unaudited) March 31, 2009 December 31, 2008
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial